Uniphar plc is a global partner to pharmaceutical and medical technology manufacturers, providing outsourced and specialized services to improve patient access to medicines in Europe and worldwide. The company operates through three main business segments: Uniphar Medtech, which distributes medical devices; Uniphar Pharma, which offers high-value services across the product life cycle; and Uniphar Supply Chain + Retail. Uniphar serves pharmacomedical manufacturers and supplies products to multiple countries, leveraging digital technology and expert teams to manage its client relationships.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Distribution Homepage uniphar.ie
Sector Healthcare IR page uniphar.ie/static/investors
Tags
medical device distribution, pharmaceutical distribution, supply chain services, retail services, outsourced services, product life cycle management, Uniphar Medtech, Uniphar Pharma, Uniphar Supply Chain + Retail
Press page —

Metrics

Valuation  
Market cap £ 887.74M
Market cap (USD) $ 1.191B
P/E 25.60
PEG —
P/BV 5.91
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2019
Assets 761.351M
Equity 180.92M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Holding(s) in Company Bull 0 Bear 0 Routine

Dublin | 16 September 2026: Uniphar plc (the "Company"), was notified by Allianz Global Investors GmbH on 16 September 2026 that, as of 15 September 2026, they have an interest in 10,280,876 ordinary shares of €0.08 each in the capital of the Company ("Ordinary Shares"). This represents 3.96% of the issued Ordinary Shares of the Company*.

  • Based on issued share capital figure of 259,574,298 Ordinary Shares

For further details contact:

| Uniphar Group | Tel: +353 (0) 1 428 7777 |

| Allan Smylie, Head of Strategy and IR |

| [email protected] |

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLAKABQQBKDQCD

Supplied by © Euroland.Com

Terms of Service

✓

Thanks for sharing!

AddToAny

More…

2026 Interim Results Bull 4 Bear 0 Results

Uniphar plc, an international diversified healthcare services business, announces its half year results for the six months ended 30 June 2026, delivering a strong performance with 6.9% organic3 gross profit growth and 11.2% adjusted EPS growth.

FINANCIAL HIGHLIGHTS

| | | | Growth |

| Six months ended 30 June1 | 2026 €'000 | 2025 €'000 | Reported | Constant currency2 |

| | | | | |

| Revenue | 1,591,855 | 1,485,492 | 7.2% | 7.4% |

| Gross profit | 236,490 | 219,651 | 7.7% | 8.2% |

| Uniphar Pharma | 68,523 | 64,042 | 7.0% | 8.0% |

| Uniphar Medtech | 62,683 | 57,505 | 9.0% | 9.8% |

| Uniphar Supply Chain & Retail | 105,284 | 98,104 | 7.3% | 7.3% |

| Gross profit margin (Group) % | 14.9% | 14.8% | | |

| EBITDA1 | 61,059 | 57,495 | 6.2% | 6.5% |

| EBITDA margin | 3.8% | 3.9% | | |

| Operating profit | 35,400 | 32,606 | 8.6% | 8.8% |

| Profit before tax excluding exceptional items | 31,146 | 28,704 | 8.5% | 8.8% |

| Net bank debt1 | (275,728) | (197,535) | | |

| Basic EPS (cent) | 7.7 | 6.6 | 16.7% | |

| Adjusted EPS (cent)1 | 10.9 | 9.8 | 11.2% | |

· Gross profit growth of 7.7%, of which 6.9% is organic3 reflecting strong growth across all divisions.

· Gross profit margin increased to 14.9% (June 2025: 14.8%).

· EBITDA growth of 6.2% demonstrating the execution of our strategy in each division.

· Adjusted EPS growth of 11.2% to 10.9 cent (June 2025: 9.8 cent).

· Robust liquidity with net bank debt of €275.7m (December 2025: €171.1m) and leverage at 2.4x (December 2025: 1.6x). This increase principally reflects the expected unwind of prior year working capital timing benefits as previously indicated.

· The Board has declared an interim dividend of €0.0074 per ordinary share for the period to 30 June 2026 representing an increase of 4.2% in the period (June 2025: €0.0071 per ordinary share).

· EBITDA growth is set to accelerate in the second half of 2026; underpinned by strong trading momentum.

· The Group is well positioned to deliver on Adjusted EPS expectations for the full year.

  1. Additional information are set out in Alternative Performance Measures (APMs) section.

  2. Constant currency growth is calculated by applying the prior period's actual exchange rate to the current period's result.

  3. Organic growth is calculated as the gross profit growth of the underlying business in the period adjusting for the contribution from acquisitions and disposals in the relevant period to ensure a like-for-like comparison.

STRATEGIC AND OPERATIONAL HIGHLIGHTS

· The Group delivered a strong performance in the period with Adjusted EPS growth of 11.2% to 10.9 cent with each division delivering growth consistent with its strategic objectives.

· The Group achieved organic gross profit growth of 6.9% with an increase in gross profit margin to 14.9%.

§ Uniphar Pharma delivered 7.0% organic gross profit growth against a strong prior year comparator, supported by continued progress across Global Sourcing and Pharma Services. The division remains confident in achieving double-digit organic gross profit growth for the full year.

§ Uniphar Medtech delivered 9.0% organic gross profit growth supported by broad-based demand across core specialisms, portfolio expansion into new markets and continued enhancement of the product offering.

§ Uniphar Supply Chain & Retail delivered 5.6% organic gross profit growth, with the retail network increasing by 30 pharmacies to 512 in the period, and Wholesale maintaining strong volume growth.

· Net bank debt increased in the period to €275.7m from €171.1m in December 2025, representing a leverage multiple of 2.4x. The increase primarily reflects the expected unwind of prior year working capital timing benefits in the Pharma division as previously indicated. This unwind results in a negative free cash flow conversion of 77.1% as at June 2026 (positive free cash flow conversion of 99.1% as at December 2025). The Group retains a robust liquidity position and remains disciplined in its approach to capital allocation.

· We continue to enhance our global capabilities, with the final phases of development of our state-of-the-art facilities in the Netherlands and UK completing in 2026. The new high-tech distribution facility in Ireland will now go live in February 2027, with a phased roll-out during H1 2027. The revised timeline allows for additional end-to-end testing and minimises execution risk during Supply Chain's operational peak trading period in Q4.

· Return on capital employed (ROCE) for the rolling 12-month period was 14.7% (June 2025: 15.5%), remaining at the upper end of the Group's medium-term target of 12%-15%. The reported ROCE is reflective of strong profitability in the period combined with disciplined capital management.

· Sustainability remains a key focus for the Group, with continued progress across our Climate Change and Responsible Sourcing Programmes. Current initiatives include a significant solar project supporting progress towards the Group's 2030 SBTi-aligned Scope 1 and 2 emissions reduction targets, together with continued supplier engagement through the responsible sourcing programme.

· Uniphar has consistently deployed capital in a disciplined manner in both M&A and strategic investment opportunities. M&A remains an objective of the Group in delivering its medium-term growth targets, with the Group continuing to maintain an active pipeline of opportunities.

Ger Rabbette, Uniphar Group Chief Executive Officer said:

"Uniphar has delivered a strong first half, with continued organic gross profit growth across the Group. Trading continues to be robust, and the business is developing in line with our expectations. We expect to sustain this progress into the second half and remain on track to meet our growth objectives for each of our three divisions for the full year. We also remain confident in our ability to reach our €200m EBITDA target by 2028, with at least 80% of growth expected to be organic."

Analyst presentation

A conference call for investors and analysts will be held at 09:00 (BST), today, 08 September 2026. Analysts and investors who wish to participate should visit www.uniphar.ie to register.

A copy of the presentation and announcement will be available on our website at the time of the call.

Holding(s) in Company Bull 0 Bear 0 Routine

| X WhatsApp Email LinkedIn Facebook WeChat Print Share | Close |

RNS Number : 0866T

Uniphar PLC

02 September 2026

Standard Form TR-1 Voting rights attached to shares- Article 12(1) of directive 2004/109/EC Financial instruments - Article 11(3) of the Commission Directive 2007/14/EC[i]

  1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached [ii]:

UNIPHAR PLC

  1. Reason for the notification (please tick the appropriate box or boxes):

[ X ] an acquisition or disposal of voting rights

[ ] an acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

[ ] an event changing the breakdown of voting rights

  1. Full name of person(s) subject to the notification obligation[iii]:

BlackRock, Inc.

  1. Full name of shareholder(s) (if different from 3.)[iv]:

See Section 9

  1. Date of the transaction and date on which the threshold is crossed or reached[v]: 31/08/2026

  2. Date on which issuer notified: 01/09/2026

  3. Threshold(s) that is/are crossed or reached:

Holdings for BlackRock, Inc. have gone above 3%.

  1. Notified details:

| A) Voting rights attached to shares |

| Class/type of shares (if possible using the ISIN CODE) | Situation previous to the Triggering transaction [vi] | Resulting situation after the triggering transaction[vii][viii] |

| Number of Shares[ix] | Number of Voting rights[x] | Number of shares[xi] | Number of voting rights[xii] | % of voting rights |

| Direct | Direct[xiii] | Indirect[xiv] | Direct | Indirect |

| IE00BJ5FQX74 | N/A | Below 3% | N/A | N/A | 7,852,969 | N/A | 3.02% |

| SUBTOTAL A (based on aggregate voting rights) | | | | 7,852,969 | 3.02% |

| B) Financial Instruments |

| Resulting situation after the triggering transaction[xv] |

| Type of financial instrument | Expiration Date[xvi] | Exercise/Conversion Period/ Date[xvii] | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |

| | | | | |

| | | | | |

| | SUBTOTAL B (in relation to all expiration dates) | | |

| Total (A+B) | number of voting rights | % of voting rights |

| 7,852,969 | 7,852,969 | 3.02% |

  1. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable[xviii]:

Each of the following entities, which are wholly owned subsidiaries of BlackRock, Inc., hold the following interests in voting rights in their capacity as Investment Manager on behalf of clients:

| Investment Manager | Voting Rights | % |

| BlackRock Fund Advisors | 2,720,081 | 1.04% |

| BlackRock Investment Management (UK) Limited | 2,173,189 | 0.83% |

| BlackRock Institutional Trust Company, National Association | 2,085,245 | 0.80% |

| BlackRock Advisors (UK) Limited | 598,695 | 0.23% |

| BlackRock Asset Management Canada Limited | 275,760 | 0.10% |

  1. In case of proxy voting: [name of the proxy holder] will cease to hold [number] voting rights as of [date].

  2. Additional information:

Done at 12 Throgmorton Avenue, London, EC2N 2DL, U.K. on 01 September 2026

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLAKBBBFBKKACK

Supplied by © Euroland.Com

Terms of Service

✓

Thanks for sharing!

AddToAny

More…

Prompts

Uniphar plc (ticker UPR), listed in United Kingdom.

ETFs Holding Uniphar plc

ETF Weight in ETF Shares Market value As of
AVDS 0.03% 20,209 $ 96.785K Nov 16, 2026
AVSD 0.01% 5,996 $ 28.716K Nov 16, 2026
AVDE 0.00% 160,227 $ 767.358K Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
UPR canonical Common share — GB lse 3.69 GBP 2026-05-13
UPR Common share — IE euronext — —